SOP Toolkit in Diverse Practices Implemented & Tested With RE-AIM
NCT01868334 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70549
Last updated 2023-10-06
Summary
The purpose of this study is to test whether or not the 4 Pillars Toolkit increases adult Influenza, pneumococcal polysaccharide vaccine (PPSV), tetanus, adult diphtheria and acellular pertussis vaccine (Tdap/Td) vaccination rates. The vaccines are all FDA licensed vaccines and to be used according to national guidelines. The investigators will conduct a randomized cluster trial of this toolkit in diverse primary care practice with electronic medical records (EMRs).
Conditions
- Adult Influenza Vaccinations
- Adult PPSV Vaccinations
- Adult Tdap/Td Vaccinations
Interventions
- BEHAVIORAL
-
Pillar 1: Convenient Vaccination Services
Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond. Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap.
- BEHAVIORAL
-
Pillar 2: Patient notification
Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, "on-hold" messages, clinic websites, and/or social media
- BEHAVIORAL
-
Pillar 3: Enhanced Office Systems
Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates
- BEHAVIORAL
-
Pillar 4: Motivation
Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
Sponsors & Collaborators
-
Centers for Disease Control and Prevention
collaborator FED -
Baylor College of Medicine
collaborator OTHER -
University of Pittsburgh
lead OTHER
Principal Investigators
-
Mary Patricia Nowalk, PhD, RD · University of Pittsburgh, School of Medicine, Department of Family Medicine
-
Anthony E Brown, MD MPH · Baylor College of Medicine
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-04-30
- Primary Completion
- 2015-05-31
- Completion
- 2015-12-31
Countries
- United States
Study Locations
More Related Trials
-
Project IMPACT Immunizations (IMProving America's Communities Together) Scaled Demonstration
NCT03372967 ·Status: COMPLETED
-
Nudge and Motivational Interviewing Interventions to Improve Influenza Vaccine Uptake Among Healthcare Workers in China
NCT07157163 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Health Management Training to Enhance Influenza Vaccine Immunogenicity
NCT01256515 ·Status: COMPLETED ·Phase: NA
-
A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza
NCT00706732 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Universal Influenza A Vaccine in Healthy Adults
NCT05155319 ·Status: COMPLETED ·Phase: PHASE1
-
Attitudes Toward Human Papillomavirus and Influenza Vaccination Among Mothers of Early Adolescents
NCT02358083 ·Status: COMPLETED ·Phase: NA
-
Comparison of Delivery Routes of Flu Vaccine in Adults
NCT00170547 ·Status: COMPLETED ·Phase: PHASE2
-
Revealing Protective Immunity to Influenza Using Systems Immunology
NCT06501963 ·Status: COMPLETED ·Phase: PHASE4
-
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
NCT00616928 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine
NCT01465035 ·Status: COMPLETED ·Phase: PHASE1
-
Adult Influenza Vaccination Text Message Reminders
NCT01942824 ·Status: COMPLETED ·Phase: NA
-
Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
NCT01045564 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine
NCT01201902 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines
NCT01111968 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Text Message for Influenza Vaccination
NCT01761734 ·Status: COMPLETED ·Phase: NA
-
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
NCT06602024 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old
NCT01356342 ·Status: COMPLETED ·Phase: PHASE4
-
H5N1 Priming and Boosting Strategies
NCT00703053 ·Status: COMPLETED ·Phase: PHASE2
-
Improving Influenza Vaccination Rates Among Health Care Professionals
NCT00404664 ·Status: COMPLETED ·Phase: NA
-
Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)
NCT03023709 ·Status: TERMINATED ·Phase: PHASE4
-
Collaborative Efforts to Increase Flu Vaccination
NCT01403649 ·Status: COMPLETED ·Phase: NA
-
Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects
NCT00630331 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults
NCT00333398 ·Status: COMPLETED ·Phase: PHASE3
-
Cluster RCT - Evaluating Effectiveness of a Guide and Tools for Influenza Immunization Campaign Planners
NCT01207518 ·Status: UNKNOWN ·Phase: NA
-
To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults
NCT01750814 ·Status: COMPLETED ·Phase: PHASE3